I reported previously (Feb 2012) on Israel’s Medi-Tate and its non-invasive treatment for benign prostate enlargement.  Now Japan’s Olympus Corporation has invested $20 million in Medi-Tate and will market Medi-Tate’s iTind implant in several countries.

https://www.calcalistech.com/ctech/articles/0,7340,L-3749102,00.html